Avalo Therapeutics, Inc. - COMMON STOCK (AVTX)
CUSIP: 05338F306
Q1 2024 13F Holders as of 31 Mar 2024
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 22,853,024
- Total 13F shares
- 87,507
- Share change
- +64,537
- Total reported value
- $1,897,924
- Price per share
- $21.75
- Number of holders
- 18
- Value change
- +$1,405,693
- Number of buys
- 10
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05338F306:
Top shareholders of AVTX - Avalo Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
765,828
|
$397,771 | — | 26 Jun 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.07%
|
15,876
|
$144,472 | — | 31 Dec 2023 | |
| NATIXIS |
13F
|
Company |
0.02%
|
4,604
|
$43,278 | — | 31 Dec 2023 | |
| James Archie Harrell Jr. |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
36,766
|
$19,096 | — | 10 Dec 2021 | |
| H. Jeffrey Wilkins |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
33,373
|
$17,334 | — | 10 Dec 2021 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,766
|
$16,071 | — | 31 Dec 2023 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0%
|
522
|
$4,000 | — | 31 Dec 2023 | |
| Schond L. Greenway |
3/4/5
|
CFO |
—
class O/S missing
|
3,883
|
$2,017 | — | 10 Dec 2021 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
138
|
$1,000 | — | 31 Dec 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
44
|
$400 | — | 31 Dec 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
8
|
$73 | — | 31 Dec 2023 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
2
|
$18 | — | 31 Dec 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
2
|
$18 | — | 31 Dec 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
2
|
$18 | — | 31 Dec 2023 | |
| First Horizon Advisors, Inc. |
13F
|
Company |
0%
|
1
|
$9 | — | 31 Dec 2023 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1
|
$9 | — | 31 Dec 2023 | |
| Stephen Smolinski |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
400,000
|
— | — | 04 Jan 2022 | |
| Michael F. Cola |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
78,116
|
— | — | 01 Oct 2021 | |
| Sol J. Barer |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 15 Jun 2021 | |
| Joseph M. Miller |
3/4/5
|
Director |
—
class O/S missing
|
20,239
|
— | — | 31 Mar 2022 | |
| Suzanne Louise Bruhn |
3/4/5
|
Director |
—
class O/S missing
|
5,204
|
— | — | 10 Nov 2021 | |
| Phil Gutry |
3/4/5
|
Director |
—
class O/S missing
|
4,718
|
— | — | 01 Dec 2021 | |
| Magnus Persson |
3/4/5
|
Director |
—
class O/S missing
|
3,334
|
— | — | 20 Dec 2023 |
Institutional Holders of Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) as of Q1 2024
As of 31 Mar 2024,
Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,507 shares.
The largest 10 holders included
Ikarian Capital, LLC, Sio Capital Management, LLC, Affinity Asset Advisors, LLC, UBS Group AG, ADAR1 Capital Management, LLC, NATIXIS, BlackRock Inc., Tower Research Capital LLC (TRC), Banque Cantonale Vaudoise, and Royal Bank of Canada.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
12
Q1 2024 holders
18
Holder diff
6
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 Value $ | Q1 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.